Pretreatment with standard‐dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (ITP)
Objective To assess the benefits and harms to initiate corticosteroids with intravenous methylprednisolone at a conventional dose (1 mg/kg/d) to treat adults with immune thrombocytopenia (ITP). Methods Population stemmed from the prospective multicenter CARMEN registry and included newly diagnosed h...
Gespeichert in:
Veröffentlicht in: | European journal of haematology 2018-05, Vol.100 (5), p.412-418 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objective
To assess the benefits and harms to initiate corticosteroids with intravenous methylprednisolone at a conventional dose (1 mg/kg/d) to treat adults with immune thrombocytopenia (ITP).
Methods
Population stemmed from the prospective multicenter CARMEN registry and included newly diagnosed hospitalized ITP adults with platelet counts |
---|---|
ISSN: | 0902-4441 1600-0609 |
DOI: | 10.1111/ejh.13032 |